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Abstract
Background: The intratumoral infiltration of T cells, especially memory T cells, is associated with a favorable
prognosis in early colorectal cancers. However, the mechanism underlying this process remains elusive. This study
examined whether high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) molecule,
is involved in the infiltration of T cells and disease progression in locally advanced colon cancer.
Methods: Seventy-two cases of pathologically-confirmed specimens were obtained from patients with stage IIIB
(T3N1M0) colon cancer who underwent radical resection between January 1999 and May 2002 at the Cancer
Center of Sun Yat-Sen University. The density of tumor-infiltrating lymphocytes (TILs) within the tumor tissue and
the expression of HMGB1 in the cancer cells were examined via immunohistochemical analysis. The phenotype of
CD45RO+ cells was confirmed using a flow cytometric assay. The association between HMGB1 expression, the
density of TILs, and the 5-year survival rate were analyzed.
Results: The density of CD45RO+ T cells within the tumor was independently prognostic, although a higher
density of CD3+ T cells was also associated with a favorable prognosis. More importantly, the expression of HMGB1
was observed in both the nucleus and the cytoplasm (co-expression pattern) in a subset of colon cancer tissues,
whereas nuclear-only expression of HMGB1 (nuclear expression pattern) existed in most of the cancer tissues and
normal mucosa. The co-expression pattern of HMGB1 in colon cancer cells was inversely associated with the
infiltration of both CD3+ and CD45RO+ T cells and 5-year survival rates.
Conclusions: This study revealed that the co-expression of HMGB1 is inversely associated with the infiltration of
CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer, indicating that the distribution patterns of
HMGB1 might contribute to the progression of colon cancer via modulation of the local immune response.
Background
Colorectal cancer is one of the most common causes of
cancer deaths worldwide [1]. The median overall survival
of patients with metastatic colorectal cancer has
increased from 12 months to approximately 24 months
over the past decade as a result of improvements in sys-
temic therapies, including new chemotherapeutic agents
such as irinotecan and oxaliplatin and monoclonal anti-
bodies against epidermal growth factor receptor (EGFR)
and vascular endothelial growth factor (VEGF). However,
the 5-year survival of patients is still poor [2-5]. Thus,
one of the main challenges for the treatment of colorectal
cancer remains to identify new strategies beyond
chemotherapy to inhibit disease progression.
Colorectal cancers are characterized by infiltration
with multiple stromal cells, among which are tumor-
infiltrating lymphocytes (TILs) that act as prognostic
and predictive factors [6-15]. TILs include natural killer
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Th1, Th2, Th17, and Treg cells. Although the role of
TILs in tumor progression is controversial, CD45RO+
T cells have been identified as the main anti-tumoral
effectors in early colorectal cancers. Hierarchical cluster-
ing has shown that markers of T-cell migration, activa-
tion, and differentiation are increased in tumors without
signs of early metastatic invasion. These tumors have an
increased number of CD8+ T cells, ranging from early
memory (CD45RO+, CCR7-, CD28+, and CD27+)
to effector memory (CD45RO+, CCR7-, CD28-, and
CD27-) T cells. The presence of high levels of infiltrat-
ing memory CD45RO+ T cells is correlated with the
absence of signs of early metastatic invasion, a less
advanced pathologic stage, and increased survival, which
has been confirmed in several series of patients [16,17].
These correlations indicates that protective immune
responses exist in a subset of colorectal cancer patients.
Activated tissue-resident memory T cells, which have a
potent lytic potential with the expression of perforin
and granzyme B, are not only capable of providing
immediate effector function at the site of cancer cells
but can also generate an effective secondary immune
response [18-21]. Radiotherapy and some chemothera-
peutics have the potential to induce the immunogenic
death of cancer cells and subsequently activate memory
T cells. Furthermore, clinical trials have shown that the
efficacy of chemotherapy against colon cancer can be
improved when combined with cytokines [22-27]. These
data indicate that the activation of memory T cells that
have infiltrated into tumor tissues might be a promising
therapeutic strategy.
Tissue-resident memory T cells result from the acute
immune response, which may be induced by damage-
associated molecular pattern molecules (DAMPs). High-
mobility group box 1 (HMGB1), previously named
HMG1, amphoterin, and sulfoglucuronyl carbohydrate
binding proteinis a DAMP. Under physiologic condi-
tions, HMGB1 localizes in the nucleus. HMGB1 is
released into the extracellular matrix by spontaneous
release or by dying cells. HMGB1 is a multi-functional
protein that accelerates cell growth, invasion, and angio-
genesis in cancer tissues, induces apoptosis in macro-
phages, and promotes immune responses [28-31]. With
respect to modulation of the immune response, HMGB1
binds to surface receptors expressed on dendritic cells
(DCs), leading to the maturation of DCs, antigen pro-
cessing, and a subsequent protective effect. There is also
evidence that HMGB1 induces immune tolerance by
interfering with the antigen-presenting process and
decreasing the number of DCs or by binding to the
TLR9 agonist, which leads to human plasmacytoid DC
suppression [32-36]. In addition, extracellular HMGB1
triggers the inflammatory cascade through multiple
pathways, facilitating progression of the tumor.
Because HMGB1 has a dual effect on tumor progres-
sion, the feasibility of targeting the release of HMGB1
r e m a i n se l u s i v e .T ot h i se n d ,t h i ss t u d yd e t e r m i n e d
whether the expression of HMGB1 is related to the
infiltration of T cells and patient prognosis in locally
advanced colon cancers.
Methods
Materials
Seventy-two cases of pathologically-confirmed specimens
matched with adjacent normal mucosa were obtained
from patients with stage IIIB (T3N1M0; AJCC, 2002)
colon cancer between January 1999 and May 2002 at the
Cancer Center of Sun Yat-Sen University in Guangzhou,
China (Table 1). All of the patients underwent radical
resection and 5-FU-based adjuvant chemotherapy post-
operatively for 6 months. Patients were evaluated every
3m o n t h sd u r i n gt h e1
st year, every 6 months in the 2
nd
year, and by telephone or mail communication once every
year thereafter for a total of 5 years. If recurrence or
metastasis occurred, 5-FU-based chemotherapy was given
according to the NCCN guidelines. Overall survival was
defined as the time from surgery to death. Alternatively,
censoring was done at the last known date the patient was
alive. This study was approved by the institutional ethical
review committee of Sun Yat-Sen University Cancer
Center.
Immunohistochemical assay and scoring systems
Formalin-fixed, paraffin-embedded archived tissues were
cut into 4-μm sections. The size of each tissue section
Table 1 Patient Characteristics (N = 72)
Characteristic No. of patients (%)
Age, years
< 60 33(45.8)
≥60 39(54.2)
Gender
Male 40(55.6)
Female 32(44.4)
Tumor sites
Left hemicolon 46(63.9)
Right hemicolon 26(36.1)
Pathological grade
G1 10(13.9)
G2 54(75.0)
G3 8(11.1)
Survival time, months
≥60 52(72.2)
< 60 20(27.8)
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Page 2 of 13was about 1.0 cm×1.5 cm. Then, the sections were
de-waxed, rehydrated, blocked with hydrogen peroxide,
and the antigens were retrieved in a microwave in
10 mM citrate buffer (pH 6.0) for 10 minutes and
cooled to room temperature. After blocking with sheep
serum, the sections were incubated overnight at 4°C
with either rabbit polyclonal antibody against human
HMGB1 at a dilution of 1:1000 (Abcam, Cambridge,
MA, USA) or mouse monoclonal antibody against
human CD3, CD45RO, CD4, CD8, and CD56. All of
these antibodies (Zymed, San Diego, CA, USA) were
diluted 1:100. Subsequently, biotinylated secondary anti-
bodies and streptavidin-biotinylated horseradish peroxi-
dase complex were used. The sections were developed
with diaminobenzidine tetrahydrochloride (DAB) and
counterstained with hematoxylin. Negative controls
were employed in which the primary antibody was
replaced by phosphate-buffered solution (PBS).
The density of TILs within the tumors and the expres-
sion of HMGB1 in cancer cells were scored with two
scoring systems. Hussein’s method was used to score
the density of TILs as follows: 1) the cells were counted
in at least 10 different fields of each section, and the
size of each high-power field (×400) was about 300
μm×300 μm; 2) the cells were counted in the tumor
stroma; 3) the areas of highest density were chosen; 4)
necrotic areas were avoided; 5) two observers counted
t h ec e l l sa tt h es a m et i m ea n di nt h es a m ef i e l du s i n ga
multiple-lens microscope; and 6) the results were
expressed as the mean ± standard error of the mean
[37]. The expression of HMGB1 was interpreted via
immunoreactivity using the 0-4 semi-quantitative system
derived from Soumaoro [38] for both the intensity of
staining and the percentage of positive cells (labeling
frequency percentage). The intensity of nuclear or cyto-
plasmic staining was grouped into the following four
categories: no staining/background of negative controls
(score = 0), weak staining detectable above background
(score = 1), moderate staining (score = 2), and intense
staining (score = 3). The labeling frequency was scored
as 0 (≤1%), 1 (1%-24%), 2 (25%-49%), 3 (50%-74%), and
4( ≥75%). The sum index was obtained by totaling the
intensity and percentage scores, as follows: (-), (+), (++),
and (+++) indicated sum-indexes of 0-1, 2-3, 4-5, and
6-7, respectively; (-) and (+) were defined as no or mod-
est expression, and (++) and (+++) were defined as
strong expression. Each section was independently
scored by two pathologists. If an inconsistency occurred,
a third pathologist was consulted to achieve consensus.
Double immunohistochemistry for HMGB1 and CD45RO
Double immunohistochemical staining was performed
with a Polymer kit (GBI, Seattle, WA, USA). The sec-
tions were simultaneously incubated with two primary
antibodies derived from different species. After blocking
nonspecific binding with goat serum, the sections were
incubated overnight at 4°C with a rabbit anti-human
HMGB1 polyclonal antibody (1:1000; Abcam, Cam-
bridge, MA, USA) and a mouse anti-human CD45RO
monoclonal antibody (1:100; Zymed, San Diego, CA,
USA) simultaneously. After washing in PBS, the sections
were incubated with both alkaline phosphatase-labeled
goat anti-rabbit IgG antibodies and horse radish peroxi-
dase-labeled goat anti-mouse IgG antibodies with a defi-
nite percentage for 30 minutes at room temperature.
After three washes with PBS, sections were developed
sequentially with DAB and AP-Red and counterstained
with hematoxylin. Negative controls were employed in
which both of the primary antibodies were replaced
with PBS.
Flow-cytometric analysis
Fresh tumor specimens were processed via sterile
mechanical dissection. The tissue was cut into small
pieces and stirred for 2 hours at 37°C in an enzymatic
bath containing RPMI 1640 (Invitrogen, San Diego,
CA, USA) and HEPES buffer (20 mmol/L) containing
penicillin/streptomycin (120 μg/ml and 100 ug/ml,
respectively), fungizone (0.25 mg/ml), ceftazidime
(50 μg/ml), collagenase type III (200 U/ml), and DNase
type I (100 U/ml). The suspension was then filtered
through two wire grids (70 and 40 μm), and the cells
were washed three times with Hank’s balanced salt
solution (HBSS). Subsequently, cells were separated on
a Percoll density gradient (Pharmacia Biotech AB,
Uppsala, Sweden) for 30 min at 1500 × g at room tem-
perature. The dense layer, enriched for lymphocytes,
was collected and washed. Then the cells were incu-
bated for 30 minutes at 4°C with antibodies conjugated
to APC against CD3 (Biolegend, San Diego, CA, USA)
and phycoerythrin (PE) against CD45RO (Biolegend,
San Diego, CA, USA). Analyses were performed with a
five-color fluorescence-activated cell sorter (FC500;
Beckman-Coulter, Fullerton, CA, USA) and Cxp cyt-
ometer software (Beckman-Coulter, Fullerton, CA,
USA). Immune subpopulations were measured as a
percentage of the total number of all cells and a
percentage of the total number of CD3+ cells.
Statistical analysis
The correlation between the density of TILs or HMGB1
expression with patient characteristics and the correla-
tion between the density of TILs and levels or subcellular
location of HMGB1 were analyzed with a chi-square test
or Fisher’s exact test. The following factors were assessed
with both univariate and multivariate analyses to deter-
mine their influence on overall survival: gender, age,
pathologic grade, tumor site, the density of CD3+ cells,
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Page 3 of 13the density of CD45RO+ cells, and the level or subcellu-
lar location of HMGB1 expression within colon cancer
tissues. Kaplan-Meier curves were used to estimate the
distributions of those variables in relation to survival,
which were compared using the log-rank test. The Cox
regression model was used to correlate assigned variables
with overall survival. All statistical analyses were carried
out using SPSS 13.0 software (SPSS Inc., Chicago, IL,
USA). Statistical significance was assumed for a two-
tailed P < 0.05.
Results
Patterns of TIL infiltration and HMGB1 expression within
stage IIIB colon cancer tissues
CD3+ and CD45RO+ cells were observed in all cases
in the tumor stroma and the adjacent normal mucosa dif-
ferent extents. Both antigens stained the cell membrane.
In addition, we performed immunostaining against CD4,
CD8, and CD56 in 10 of the tissue sections to determine
which of these proteins might play an important role in
this group of patients. Among the CD3+ cells, CD8+
cells outnumbered CD4+ cells, while CD56+ cells were
rare (Fig. 1, 2. To confirm the phenotype of the CD45RO
+ cells, co-expression of CD3 with CD45RO was exam-
ined in five fresh cancer tissues via flow cytometry, which
indicated that 72% of all tumor-infiltrating CD45RO+
lymphocytes were also CD3-positive (Fig. 3).
Although HMGB1 staining existed only in the nucleus
in normal mucosa, co-expression of nuclear and cyto-
plasmic HMGB1 (co-expression pattern) existed in a
subset of cancer tissues (12/65 [18.5%]), whereas most
of the cancer tissues only showed nuclear staining of
HMGB1 (nuclear expression pattern; 53/65 [81.5%];
Table 2, Fig. 4).
Figure 1 Patterns of TILs within stage IIIB colon cancer tissues. A high density of CD3+ cells infiltrated into the colon cancer stroma (×400, A),
a low density of CD3+ cells infiltrated into the colon cancer stroma (×400, B), a high density of CD45RO+ cells infiltrated into the colon cancer
stroma (×400, C), and a low density of CD45RO+ cells infiltrated into the colon cancer stroma (×400, D, “↑"refers to tumor tissue). All of the antigens
were immunolocalized to the membrane.
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density of CD3+ or CD45RO+ cells
The density of TILs within the tumors was within the
75
th percentile for all those specimens in which the sur-
vival difference between the “high” and “low” groups
was the largest [17]. The cut-off values for the density
of CD3+ and CD45RO+ cells were 16 and 24 cells per
high-power field in the center of the tumor, respectively.
Thus, the density of CD3+ cells was recorded as high if
> 16 cells were observed per high-power field, and the
same cutoff used for CD45RO+ cells. The log-rank test
was used to compare the level of HMGB1 with the den-
sity of CD3+ and CD45RO+ cells within the tumor.
A stronger expression (++-+++) of HMGB1 was asso-
ciated with a higher density of both CD3+ and CD45RO
+ cells (Table 3, Fig. 5). Furthermore, the log-rank test
was used to compare the subcellular localization of
HMGB1 with the density of CD3+ and CD45RO+ cells
within the tumor. The co-expression pattern of HMGB1
in the nucleus and cytoplasm was inversely associated
with infiltration of both CD3+ and CD45RO+ cells,
respectively (Table 4, Fig. 5).
Relationship between the density of TILs, HMGB1, clinical
characteristics, and 5-year survival rate as analyzed via
univariate analysis
The log-rank test was used to compare the density of
CD3+ cells and CD45RO+ cells and the level of
HMGB1 with patient characteristics. The density of
CD3+ cells within the tumor stroma was associated with
pathologic grades (P=0.023), i.e., a lower pathologic
grade was associated with less CD3+ cell infiltration.
However, neither the density of the CD45RO+ cells nor
the levels of HMGB1 were associated with any of the
clinical characteristics.
By the end of the 5-year follow-up period, 52 patients
were alive, making the 5-year survival rate equal to 72%
in this group of patients. Kaplan-Meier survival analysis
Figure 2 Subtype of CD3+ cells within stage IIIB colon cancer tissues. A high density of CD3+ cells infiltrated into the colon cancer stroma
(×400, A); CD4+ cells infiltrated into the colon cancer stroma (×400, B), CD8+ cells infiltrated into the colon cancer stroma (×400, C), and CD56+
cells infiltrated into the colon cancer stroma (×400, D). All of the antigens were immunolocalized to the membrane.
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CD45RO+ cells within the tumor was associated with a
higher 5-year survival rate (Fig. 6). However, the associa-
tion between the patterns of HMGB1 expression and
5-year survival rate was complicated. The survival curves
crossed at 24 months between patients with nuclear-
only expression of HMGB1 and those with co-expres-
sion of nuclear and cytoplasmic HMGB1 (Fig.7A).
Kaplan-Meier survival analysis revealed no statistical
difference in survival between the patients with nuclear-
only expression of HMGB1 and those with co-expres-
sion of nuclear and cytoplasmic HMGB1 within
24 months after surgery. After 24 months, the patients
with the co-expression of nuclear and cytoplasmic
HMGB1 showed a lower 5-year survival rate compared
with the patients with nuclear-only expression of
HMGB1 (Table 5, Fig. 7B).
Relationship between the density of TILs, the level or
subcellular location of HMGB1, clinical characteristics, and
5-year survival rate as analyzed via multivariate survival
analysis
The Cox regression model revealed that only those
patients with a higher density of CD45RO+ cells within
the tumor stroma had a longer survival, whereas no
relationship was observed between the survival and the
d e n s i t yo fC D 3 +c e l l s .T h e r ew a sa l s on or e l a t i o n s h i p
between the survival and the levels or the subcellular
distribution (nucleus only or nucleus combined with
cytoplasm) of HMGB1 in primary tumors. These results
indicated that in this group of patients, the density of
CD45RO+ cells within the tumor was independently
prognostic (Table 6). The same result occurred in the
time-dependent multivariate survival analysis (data not
shown).
Discussion
To determine the role of HMGB1 in the progression of
colon cancer, this study examined the patterns of
Figure 3 Co-expression of CD3 and CD45RO antigens among TILs analyzed with flow cytometry.
Table 2 Patterns of HMGB1 expression in stage IIIB colon
cancers (N = 72)
HMGB1 expression
0 + ++-+++
nuclear
only
nuclear and
cytoplasmic
nuclear
only
nuclear only nuclear and
cytoplasmic
7 20 5 33 7
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Page 6 of 13Figure 4 Expression of HMGB1 in colon cancer and the adjacent normal mucosa. Nuclear staining of HMGB1 (×100 in A and ×400 in B)
and nuclear and cytoplasmic staining of HMGB1 (×100 in C and ×400 in D).
Table 3 Relationship between the expression of HMGB1 and the density of TILs as well as patient characteristics
(N = 72)
Characteristic HMGB1 expression
(-)- (+) (++)-(+++)
P
Gender 0.058
Male 22 18
Female 10 22
Age, years 0.113
≥60 14 25
<60 18 15
Tumor sites 0.476
Left hemicolon 19 27
Right hemicolon 13 13
Pathological grade 0.182
G1 46
G2 22 32
G3 62
Density of CD3+cells (cells per high-power field) 0.013
≥16
<16 20 35 0.006
Density of CD45RO+cells (cells per high-power field) 12 5
≥24 19 35
<24 13 5
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Page 7 of 13Figure 5 Double staining of HMGB1 and CD45RO+ cells in stage IIIB colon cancer (red staining of HMGB1 in cancer cells and brown
staining of CD45RO+ cells in the stroma). Strong nuclear staining of HMGB1 was associated with a high density of CD45RO+ cells infiltrating
into colon cancer tissues (×100 in A and ×400 in B, “↑"refers to nuclear staining in cancer cells). Strong nuclear and cytoplasmic staining of
HMGB1 was also associated with a low density of CD45RO+ cells infiltrating into colon cancer tissues (×100 in C and ×400 in D, “↑"refers to
nuclear or cytoplasmic staining in cancer cells).
Table 4 Relationship between subcellular localization of HMGB1 and density of TILs (N = 65)
Subcellular localization of HMGB1 P value
nuclear only nuclear and cytoplasmic
Density of CD3+cells (cells per high-power field)
≥16 47 5 0.000
<16 6 7
Density of CD45RO+cells (cells per high-power field)
≥24 46 5 0.0001
<2 4 7 7
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tration of T cells and the 5-year survival rate in patients
with stage IIIB colon cancer. The results showed that
the density of CD45RO+ T cells within the cancer tissue
was independently prognostic. More importantly, the
co-expression pattern of nuclear and cytoplasmic
HMGB1 in cancer cells was inversely related to the infil-
tration of CD3+ or CD45RO+ T cells and patient 5-year
survival rate. These data indicate that the pattern of
HMGB1 expression is related to the progression of
colon cancer.
The role of TILs in colorectal cancer has been dis-
cussed extensively during the past 3 decades, but con-
troversy continues. Recently, two studies have focused
on the role of memory T cells in the progression of col-
orectal cancer. Pagès et al. [16] concentrated on the role
of TILs in the early metastatic invasion of 959 cases of
colorectal cancer and observed increasing levels of TILs,
especially CD45RO+ memory cells, in tumors without
pathologic signs of early metastatic invasion. The
increasing levels of TILs were correlated with a less
advanced pathologic stage and increased survival, indi-
cating the potential of CD45RO+ memory cells for
limiting early metastasis of colorectal cancer. Galon et
al. [17] explored the role of the adaptive immune
response in controlling growth and recurrence in 454
cases of human colorectal cancer and found that
patients with a higher density of CD3+ and CD45RO+
cells in the tumor center and the invasive margins of
the tumor samples had prolonged disease-free survival,
indicating that the type, density, and location of immune
cells within the tumor samples were predictors of survi-
val. Both of these studies revealed the protective role of
CD45RO+ memory cells in early colorectal cancer. The
present study revealed that the infiltration of CD45RO+
cells was also protective in locally advanced colon can-
cer. As 72% of CD45RO+ cells were also positive for
CD3, the protective CD45RO+ cells in colon cancer
should be predominantly CD3+ CD45RO+ memory
T cells. Although a higher density of CD3+ T cells was
also associated with a favorable prognosis in univariate
analysis, this prognostic value was not apparent in mul-
tivariate analysis, an observation that is also consistent
with a recent study [39].
Since the memory T cells residing in colon cancers
result from an acute immunologic response, this study
further examined whether HMGB1 was involved in this
process. A higher level of HMGB1 was associated with a
poorer prognosis or more malignant phenotypes in mul-
tiple solid tumors, such as nasopharyngeal, lung, skin,
hepatic, gastric, and prostate cancers, with the exception
of breast cancer [40-46]. Previous studies have shown
that the co-expression of RAGE and HMGB1 led to
enhanced migration and invasion by colon cancer cell
lines. Furthermore, increased RAGE expression in colon
cancers has been associated with atypia, adenoma size,
and metastasis to other organs. Additionally, stage I
Figure 6 The association between overall survival with the density of CD3+ and CD45RO+ cells as well as HMGB1 expression in stage
IIIB colon cancers. A high density of CD3+ cells within the tumor was associated with a longer 5-year survival rate (A); a high density of
CD45RO+cells within the tumor was associated with a longer 5-year survival rate (B).
Table 5 Relationship between the localization of HMGB1
and prognosis after 24 months of follow-up (N = 57)
Subcellular location of HMGB1 P
value
nuclear
only
nuclear and
cytoplasmic
Survival time
(months)
< 0.001
≥60 43 5
≥24and < 60 3 6
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Page 9 of 13tumors have relatively lower expression levels of
HMGB1, whereas stage IV tumors have near-universal
expression of HMGB1 [47-52]. However, only a few stu-
dies have shown the association between HMGB1
expression and 5-year survival in colon cancer patients.
Recent clinical evidence showed that the overexpression
of HMGB1 in colorectal cancer was related to malignant
phenotypes and shorter survival times [53-55]. To
decrease the bias from factors like TNM stage and rectal
cancers, this study analyzed specimens only from stage
IIIB colon cancer patients. The results indicated that the
co-expression of nuclear and cytoplasmic HMGB1 in
colon cancer cells was associated with a poor prognosis.
In normal colon mucosa, the expression of HMGB1 was
observed only in the nucleus. In colon cancer cells, the
co-expression pattern of HMGB1 in the nucleus and
cytoplasm was observed in a subset of cancer cells,
whereas nuclear-only expression of HMGB1 existed in
most colon cancer cells. The survival curves of patients
with the nuclear-only expression pattern and those with
a pattern of co-expression crossed at 24 months after
surgery, a result that might derive from the relatively
small number of cases in this study, as no statistically
significant difference was detected. However, Kaplan-
Meier survival analysis showed that the patients with the
pattern of co-expression of HMGB1 had a lower 5-year
survival rate after 24 months of follow-up than those
patients with HMGB1 expression in the nucleus only.
This effect suggested that the pattern of co-expression of
HMGB1 in cancer cells interfered with the long-term
survival by partially modulating the immune response in
a subset of colon cancer patients.
Because HMGB1 is a DAMP, the association between
the expression of HMGB1 and the infiltration of TILs
was further analyzed in this study. The results showed
that co-expression of nuclear and cytoplasmic HMGB1
was also inversely related to the infiltration of CD45RO
+ cells and CD3+ cells, again arguing that the effect of
the pattern of co-expression of HMGB1 on survival was
associated with the local modulation of the immunolo-
gic response by HMGB1. The mechanism underlying
this inverse association is still elusive. One possibility is
Figure 7 The association between overall survival and the subcellular localization of HMGB1 in stage IIIB colon cancers. No significant
correlation with 5-year survival for patients with nuclear or nuclear and cytoplasmic expression of HMGB1 in cancer cells was observed because
the survival curves crossed at 24 months (A), nuclear and cytoplasmic expression of HMGB1 in cancer cells was inversely associated with
prognosis after 24 months of follow-up (B).
Table 6 Multivariate survival analysis (N = 72)
B SE Wald df Sig. Exp(B) 95%CI for Lower Upper Exp(B)
Pathological grade .375 .257 2.120 1 .145 1.454 .878 2.408
Gender -.111 .270 .168 1 .682 .895 .527 1.520
Age .019 .242 .006 1 .936 1.020 .634 1.638
Tumor sites .015 .253 .004 1 .952 1.015 .619 1.666
Density of CD3+ cells -.569 .351 2.632 1 .105 .566 .285 1.126
Density of CD45RO+ cells -.883 .376 5.524 1 .019 .414 .198 .864
Level of HMGB1 .099 .300 .110 1 .740 1.105 .613 1.989
Localization of HMGB1 -.130 .229 .322 1 .570 .878 .560 1.376
Peng et al. BMC Cancer 2010, 10:496
http://www.biomedcentral.com/1471-2407/10/496
Page 10 of 13that HMGB1 secreted by colon cancers promotes the
angiogenesis switch and increases cancer cell invasive-
ness [56-59]. Another potential mechanism is that extra-
cellular HMGB1 triggers the inflammatory cascade,
modulates the local immunologic microenvironment
towards tolerance by polarizing the response of helper
T cells and improperly activating macrophages and DCs
[60-64]. There is evidence suggesting that both afore-
mentioned mechanisms might contribute to the progres-
sion of colon cancer. For example, in colon cancer cell
lines, E-selectin downregulated the cellular expression of
HMGB1 but enhanced the release of HMGB1 into the
culture medium. The released HMGB1, in turn, acti-
vated endothelial cells to express E-selectin [65]. Addi-
tionally, the higher level of HMGB1 detected in DCs
existed in the metastatic lymph nodes of colon cancer
patients [66]. Therefore, HMGB1-releasing colon cancer
cells might promote effective angiogenesis and immune
escape.
Several lines of evidence indicate that chemotherapy
or radiation therapy induce the release of HMGB1 from
dying cells, and this damage-related, acute release of
HMGB1 is involved in the protective immune response
[67-69]. This study observed that the co-expression of
HMGB1 in the nuclear and cytoplasm was associated
with poorer prognoses and lower infiltration of
CD45RO+ cells, suggesting that spontaneous release and
damage-induced release of HMGB1 might act differently
in the progression of colon cancer. However, This study
was just a descriptive one, more functional work should
be done to reveal the mechanisms underlying this pro-
cess. Therefore, different strategies should be considered
when targeting HMGB1 under the conditions of sponta-
neous chronic release and damage-related, acute release
of HMGB1 [70-72].
Conclusion
This study observed that the co-expression of nuclear
and cytoplasmic HMGB1 was inversely associated with
the infiltration of CD45RO+ cells and the 5-year survival
rate in patients with stage IIIB colon cancer. These
observations indicated that the distribution patterns of
HMGB1 contribute to the progression of colon cancer.
The co-expression of nuclear and cytoplasmic HMGB1
might be used as a marker for poor survival in patients
with local advanced colon cancer.
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